[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"notifications-list":3,"$fqdg5puhqqqk7":5},{"data":4},[],{"data":6,"error":10},{"id":7,"documentId":8,"slug":9,"name":9,"proprietary_name":10,"non_proprietary_name":10,"is_proprietary":10,"active_ingredient":10,"administration_route":10,"available_strength":10,"dosage_form":10,"dose_schedule":10,"drug_unit":10,"is_available_generically":10,"mechanism_of_action":10,"overdosage":10,"warning":10,"species":11,"citations":12,"dose_schedules":23,"available_strengths":62,"label_statements":72,"drug_classes":124,"specialties":130,"medical_conditions":131,"animal_species":132},1848,"c22hyamjgl311qjil7i5ishz","alfaxalone",null,[],[13,19],{"source":14,"licence":15,"source_url":16,"harvested_by":17,"retrieved_at":18},"FDA Green Book","US public domain","https:\u002F\u002Fanimaldrugsatfda.fda.gov\u002Fadafda\u002Fapp\u002Fsearch\u002Fpublic\u002FingredientsInformationExcel\u002FSection2ActiveIngredients","load-reference-corpus.cjs","2026-09-07",{"source":20,"licence":21,"source_url":22,"harvested_by":17,"retrieved_at":18},"UK VMD PID","OGL v3.0","https:\u002F\u002Fwww.vmd.defra.gov.uk\u002Fproductinformationdatabase\u002Fdownloads\u002Fvmd_productinformationdatabase.xlsx",[24,31,34,37,41,44,46,51,54,59],{"id":25,"dose_text":26,"species":27,"administration_route":28,"limitation":29,"source_label":30},13640,"Administer by intravenous injection over approximately 60 seconds or until clinical signs show the onset of anesthesia, 2.2 to 9.7 mg\u002Fkilogram (kg) for cats that did not receive a preanesthetic or 1.0 to 10.8 mg\u002Fkg for cats that received a preanesthetic.","Cats","Intravenous","Administer by intravenous injection only. Federal law restricts this drug to use by or on the order of a licensed veterinarian. When using ALFAXAN, patients should be continuously monitored, and facilities for the maintenance of a patent airway, artificial ventilation, and\noxygen supplementation must be immediately available.","Alfaxan® Multidose",{"id":32,"dose_text":33,"species":27,"administration_route":28,"limitation":29,"source_label":30},13641,"Administer an intravenous bolus containing 1.1 to 1.3 mg\u002Fkg to provide an additional 7 to 8 minutes of anesthesia in preanesthetized cats; a dose containing 1.4 to 1.5 mg\u002Fkg provides an additional 3 to 5 minutes anesthesia in unpreanesthetized cats.",{"id":35,"dose_text":36,"species":27,"administration_route":28,"limitation":29,"source_label":30},13642,"Additional low doses of ALFAXAN, similar to a maintenance dose, may be required to facilitate the\ntransition to inhalant maintenance anesthesia.",{"id":38,"dose_text":39,"species":40,"administration_route":28,"limitation":29,"source_label":30},13643,"Administer an intravenous bolus containing 1.2 to 1.4 mg\u002Fkg to provide an additional 6 to 8 minutes of anesthesia in preanesthetized dogs; a dose of 1.5 to 2.2 mg\u002Fkg provides an additional 6 to 8 minutes of anesthesia in unpreanesthetized dogs.","Dogs",{"id":42,"dose_text":43,"species":40,"administration_route":28,"limitation":29,"source_label":30},13644,"Administer by intravenous injection over approximately 60 seconds or until clinical signs show the onset of anesthesia, 1.5 to 4.5 mg\u002Fkg for dogs that did not receive a preanesthetic or 0.2 to 3.5 mg\u002Fkg for dogs that received a preanesthetic.",{"id":45,"dose_text":36,"species":40,"administration_route":28,"limitation":29,"source_label":30},13645,{"id":47,"dose_text":48,"species":10,"administration_route":49,"limitation":10,"source_label":50},13646,"Induction of general anesthesia in cats: Induction dose guidelines are based on data from the field study (see EFFECTIVENESS) and range between 2.2 - 9.7 mg\u002Fkg for cats that did not receive a preanesthetic, and between 1.0 - 10.8 mg\u002Fkg for cats that received a preanesthetic. The alfaxalone induction dose in the field study was reduced by 10 - 43%, depending on the combination of preanesthetics (dose sparing effect). Dose sparing of ALFAXAN MULTIDOSE will depend on the potency, dose, and time of administration of the various preanesthetics that are used prior to induction. To avoid anesthetic overdose, titrate the administration of ALFAXAN MULTIDOSE against the response of the patient.\nAnesthesia is usually observed within 60 seconds after the start of injection, and permits intubation within 1 - 2 minutes, irrespective of preanesthetic. The duration of anesthesia from a single induction dose ranges between 15 - 30 minutes in the unpreanesthetized cat. If a preanesthetic is used, anesthetic duration may be longer, depending on the class and dose of preanesthetic. Individual anesthesia times vary.\nExamples from the field study of average induction doses (and ranges) for cats that received various preanesthetics are presented as dosing guidelines in the table. The table is for guidance only. Draw up the maximum expected target dose and administer to effect. The actual induction dose should be based on patient response.\nAlfaxalone Induction Dose Guidelines: CATS\nPreanesthetic\nAverage alfaxalone induction dose (and range) in mg\u002Fkg\nNumber of cats\nNo preanesthetic\n4.0 (2.2-9.7)\n33\nOpioid + phenothiazine\n3.2 (1.1-10.8)\n96\nBenzodiazepine + phenothiazine\n3.6 (1.5-7.1)\n23\nBenzodiazepine + opioid + phenothiazine\n2.3 (1.2-5.0)\n26\nAlpha2-adrenergic agonist with\u002Fwithout phenothiazine\n3.6 (1.1-5.0)\n15\nAlpha2-adrenergic agonist + phenothiazine with\u002Fwithout benzodiazepine or opioid\n2.9 (1.0-3.9)\n11\nAdditional doses of ALFAXAN MULTIDOSE similar to those used for maintenance (1.1 - 1.5 mg\u002Fkg) may be administered to facilitate intubation.\nMaintenance of general anesthesia in cats: Following induction of anesthesia with ALFAXAN MULTIDOSE and intubation, anesthesia may be maintained using intermittent ALFAXAN MULTIDOSE intravenous boluses or an inhalant anesthetic agent. A maintenance bolus containing 1.1 - 1.3 mg\u002Fkg provides an additional 7 - 8 minutes of anesthesia in preanesthetized cats. A dose of 1.4 - 1.5 mg\u002Fkg provides an additional 3 - 5 minutes anesthesia in unpreanesthetized cats. Clinical response may vary, and is determined by the dose, rate of administration, and frequency of maintenance injections.\nALFAXAN MULTIDOSE maintenance dose sparing is greater in cats that receive a preanesthetic. Examples from the field study of maintenance doses for preanesthetized and unpreanesthetized cats are presented as guidelines in the table. Maintenance dose and frequency should be based on the response of the individual patient.\nAlfaxalone Maintenance Dose Guidelines: CATS\nDose and Duration\nPreanesthetized Cats\nUnpreanesthetized Cats\nMaintenance anesthesia doses\n1.1 - 1.3 mg\u002Fkg\n1.4 - 1.5 mg\u002Fkg\nMean duration of anesthesia\n7-8 minutes\n3 - 5 minutes\nIn the field study, recovery times (extubation to head lift) following alfaxalone maintenance anesthesia averaged 15 minutes in cats that did not receive a preanesthetic, and 17 minutes in preanesthetized cats.\nInhalant anesthetic maintenance of general anesthesia in cats: Additional low doses of ALFAXAN MULTIDOSE, similar to a maintenance dose, may be required to facilitate the transition to inhalant maintenance anesthesia.","INTRAVENOUS","ALFAXAN MULTIDOSE",{"id":52,"dose_text":53,"species":10,"administration_route":49,"limitation":10,"source_label":50},13647,"Induction of general anesthesia in dogs: Induction dose guidelines are based on data from the field study (see EFFECTIVENESS) and range between 1.5 - 4.5 mg\u002Fkg for dogs that did not receive a preanesthetic, and between 0.2 - 3.5 mg\u002Fkg for dogs that received a preanesthetic. The alfaxalone induction dose in the field study was reduced by 23 - 50% depending on the combination of preanesthetics (dose sparing effect). Dose sparing of ALFAXAN MULTIDOSE will depend on the potency, dose, and time of administration of the various preanesthetics that are used prior to induction. To avoid anesthetic overdose, titrate the administration of ALFAXAN MULTIDOSE against the response of the patient. In the field study, the use of a preanesthetic appeared to decrease the occurrence of apnea following alfaxalone induction in dogs.\nIn dogs, ALFAXAN MULTIDOSE usually produces recumbence within 60 seconds after the start of injection, and permits intubation within 1 - 2 minutes, irrespective of preanesthetic. The duration of anesthesia from a single induction dose is approximately 5 - 10 minutes in the unpreanesthetized dog. If a preanesthetic is used, anesthetic duration may be longer, depending on the class and dose of preanesthetic. Individual anesthesia times vary.\nExamples from the field study of average induction doses (and ranges) for dogs that received various preanesthetics are presented as dosing guidelines in the table. The table is for guidance only. Draw up the maximum expected target dose and administer to effect. The actual induction dose should be based on patient response.\nAlfaxalone Induction Dose Guidelines: DOGS\nPreanesthetic\nAverage alfaxalone induction dose (and range) in mg\u002Fkg\nNumber of dogs\nNo preanesthetic\n2.2 (1.5 - 4.5)\n17\nBenzodiazepine + opioid + acepromazine\n1.7 (0.9 - 3.5)\n39\nOpioid + acepromazine\n1.6 (0.6 - 3.5)\n80\nAlpha2-agonist\n1.1 (0.21 - 2.00)\n9\nAdditional doses of ALFAXAN MULTIDOSE similar to those used for maintenance (1.2 - 2.2 mg\u002Fkg) may be administered to facilitate intubation.\nMaintenance of general anesthesia in dogs: Following induction of anesthesia with ALFAXAN MULTIDOSE and intubation, anesthesia may be maintained using intermittent ALFAXAN MULTIDOSE intravenous boluses or an inhalant anesthetic agent. A maintenance bolus containing 1.2 - 1.4 mg\u002Fkg provides an additional 6 - 8 minutes anesthesia in preanesthetized dogs. A dose of 1.5 - 2.2 mg\u002Fkg provides an additional 6 - 8 minutes of anesthesia in unpreanesthetized dogs. Clinical response may vary, and is determined by the dose, rate of administration, and frequency of maintenance injections.\nALFAXAN MULTIDOSE maintenance dose sparing is greater in dogs that receive a preanesthetic. Examples from the field study of maintenance doses for preanesthetized and unpreanesthetized dogs are presented as guidelines in the table. Maintenance dose and frequency should be based on the response of the individual patient.\nAlfaxalone Maintenance Dose Guidelines: DOGS\nDose and Duration\nPreanesthetized Dogs\nUnpreanesthetized Dogs\nMaintenance anesthesia doses\n1.2 - 1.4 mg\u002Fkg\n1.5 - 2.2 mg\u002Fkg\nMean duration of anesthesia\n6 - 8 minutes\n6 - 8 minutes\nIn the field study, recovery times (extubation to head lift) following alfaxalone maintenance anesthesia averaged 22 minutes in dogs that did not receive a preanesthetic, and 15 minutes in preanesthetized dogs.\nInhalant anesthetic maintenance of general anesthesia in dogs: Additional low doses of ALFAXAN MULTIDOSE, similar to a maintenance dose, may be required to facilitate the transition to inhalant maintenance anesthesia.",{"id":55,"dose_text":56,"species":10,"administration_route":57,"limitation":10,"source_label":58},13648,"When administering ALFAXAN MULTIDOSE IDX by intravenous injection administer slowly to effect, titrating administration against the response of the patient. Rapid administration of ALFAXAN MULTIDOSE IDX may be associated with an increased incidence of cardiorespiratory depression or apnea. The use of preanesthetics may reduce the ALFAXAN MULTIDOSE IDX induction dose. The choice and the amount of phenothiazine, alpha₂‑ adrenoreceptor agonist, benzodiazepine or opioid will influence the response of the patient to an induction dose of ALFAXAN MULTIDOSE IDX.\nWhen using ALFAXAN MULTIDOSE IDX, patients should be continuously monitored, and facilities for the maintenance of a patent airway, artificial ventilation, and oxygen supplementation must be immediately available.\nALFAXAN MULTIDOSE IDX contains preservatives. Use within 56 days of first puncture. Any unused ALFAXAN MULTIDOSE IDX remaining after 56 days should be discarded.\nThe following tables outline the dosage and administration of ALFAXAN MULTIDOSE IDX for the indicated species by major group. The doses are representative of doses published in the literature. Veterinarians are advised to consult the published literature before use of the product (see List of References at end of product insert).","INTRAMUSCULAR, INTRAPERITONEAL, INTRAVENOUS, SUBCUTANEOUS, TOPICAL","ALFAXAN MULTIDOSE IDX",{"id":60,"dose_text":61,"species":10,"administration_route":49,"limitation":10,"source_label":50},13649,"Administer by intravenous injection only. For induction, administer ALFAXAN MULTIDOSE over approximately 60 seconds or until clinical signs show the onset of anesthesia, titrating administration against the response of the patient. Rapid administration of ALFAXAN MULTIDOSE may be associated with an increased incidence of cardiorespiratory depression or apnea. Apnea can occur following induction or after the administration of maintenance boluses of ALFAXAN MULTIDOSE. The use of preanesthetics may reduce the ALFAXAN MULTIDOSE induction dose. The choice and the amount of phenothiazine, alpha2-adrenoreceptor agonist, benzodiazepine or opioid will influence the response of the patient to an induction dose of ALFAXAN MULTIDOSE.\nWhen using ALFAXAN MULTIDOSE, patients should be continuously monitored, and facilities for the maintenance of a patent airway, artificial ventilation, and oxygen supplementation must be immediately available.\nALFAXAN MULTIDOSE contains preservatives. Use within 56 days of first puncture. Any unused ALFAXAN MULTIDOSE remaining after 56 days should be discarded.\nALFAXAN MULTIDOSE should not be mixed with other therapeutic agents prior to administration.",[63,67,69],{"id":64,"strength_text":65,"dosage_form":66,"proprietary_name":30,"species":27,"source_label":30},11873,"Each milliliter contains 10 milligrams (mg) alfaxalone.","Injectable Solution",{"id":68,"strength_text":65,"dosage_form":66,"proprietary_name":30,"species":40,"source_label":30},11874,{"id":70,"strength_text":71,"dosage_form":10,"proprietary_name":10,"species":10,"source_label":50},11875,"10 mg \u002F 1 mL",[73,77,80,83,85,87,90,93,96,100,103,107,110,114,117,120],{"id":74,"kind":75,"statement":76,"species":27,"limitation":29,"source_label":30},19992,"indication","For induction of anesthesia followed by maintenance with an inhalant anesthetic",{"id":78,"kind":75,"statement":79,"species":27,"limitation":29,"source_label":30},19993,"Maintenance of general anesthesia following induction",{"id":81,"kind":75,"statement":82,"species":27,"limitation":29,"source_label":30},19994,"Induction of general anesthesia.",{"id":84,"kind":75,"statement":76,"species":40,"limitation":29,"source_label":30},19995,{"id":86,"kind":75,"statement":79,"species":40,"limitation":29,"source_label":30},19996,{"id":88,"kind":75,"statement":89,"species":40,"limitation":29,"source_label":30},19997,"Induction of general anesthesia",{"id":91,"kind":75,"statement":92,"species":10,"limitation":10,"source_label":58},19998,"ALFAXAN MULTIDOSE IDX is indicated as a sedative and anesthetic in multiple minor species*. More specifically, ALFAXAN MULTIDOSE IDX is indicated for the following:\nFor sedation and anesthesia in captive reptiles, excluding any food‑producing species**\nFor sedation and anesthesia in captive amphibians, excluding any food‑producing species**\nFor sedation and anesthesia in ornamental fish, including species used in research such as the zebrafish\nFor sedation and anesthesia in captive species and pet birds in the orders Psittaciformes, Passeriformes, and Columbiformes, excluding any food‑producing species**\nFor sedation and anesthesia in non‑human primates\nFor sedation and anesthesia in captive rodents\nFor sedation and anesthesia in captive mustelids\nFor sedation and anesthesia in captive marsupials\nFor induction of anesthesia and immobilization in captive minor species ungulates, excluding any food‑producing species**\nUse only when there is reasonable certainty that the treated animal will not be consumed by humans or food‑producing animals.\n* The term “minor species” means animals other than humans that are not major species. “Major species” means cattle, horses, swine, chickens, turkeys, dogs and cats.\n** As used on this label, a “food‑producing minor species” is considered to be a minor species of which some members are bred, cultured, farmed, ranched, hunted, caught, trapped or otherwise harvested for the purpose of having the animals or edible products of the animals commercially distributed for consumption by humans or food‑producing animals in the United States.",{"id":94,"kind":75,"statement":95,"species":10,"limitation":10,"source_label":50},19999,"ALFAXAN MULTIDOSE is indicated for the induction and maintenance of anesthesia and for induction of anesthesia followed by maintenance with an inhalant anesthetic, in cats and dogs.",{"id":97,"kind":98,"statement":99,"species":10,"limitation":10,"source_label":58},20000,"contraindication","ALFAXAN MULTIDOSE IDX is contraindicated in animals with a known sensitivity to ALFAXAN MULTIDOSE IDX or its components, or when general anesthesia and\u002For sedation are contraindicated. Do not use in any minor species animal that may become eligible for consumption by humans or food‑producing animals.",{"id":101,"kind":98,"statement":102,"species":10,"limitation":10,"source_label":50},20001,"ALFAXAN MULTIDOSE is contraindicated in cats and dogs with a known sensitivity to ALFAXAN MULTIDOSE or its components, or when general anesthesia and\u002For sedation are contraindicated.",{"id":104,"kind":105,"statement":106,"species":10,"limitation":10,"source_label":50},20002,"warning","Animal safety: When using ALFAXAN MULTIDOSE, patients should be continuously monitored, and facilities for the maintenance of a patent airway, artificial ventilation, and oxygen supplementation must be immediately available.\nRapid bolus administration or anesthetic overdose may cause cardiorespiratory depression, including hypotension, apnea, hypoxia, or death. Arrhythmias may occur secondary to apnea and hypoxia. In cases of anesthetic overdose, stop ALFAXAN MULTIDOSE administration and administer treatment as indicated by the patient’s clinical signs. Cardiovascular depression should be treated with plasma expanders, pressor agents, anti-arrhythmic agents or other techniques as appropriate for the treatments of the clinical signs.\nHuman safety: Not for human use. Keep out of the reach of children.\nALFAXAN MULTIDOSE should be managed to prevent the risk of diversion, through such measures as restriction of access and the use of drug accountability procedures appropriate to the clinical setting.\nExercise caution to avoid accidental self-injection. Overdose is likely to cause cardiorespiratory depression (such as hypotension, bradycardia and\u002For apnea). Remove the individual from the source of exposure and seek medical attention. Respiratory depression should be treated by artificial ventilation and oxygen.\nAvoid contact of this product with skin, eyes, and clothes. In case of contact, eyes and skin should be liberally flushed with water for 15 minutes. Consult a physician if irritation persists. In the case of accidental human ingestion, seek medical advice immediately and show the package insert or the label to the physician.\nNote to physician: This product contains an injectable anesthetic.",{"id":108,"kind":105,"statement":109,"species":10,"limitation":10,"source_label":58},20003,"Animal Safety: Rapid bolus administration or anesthetic overdose may cause cardiorespiratory depression, including hypotension, apnea, hypoxia, or death. Arrhythmias may occur secondary to apnea and hypoxia. In cases of anesthetic overdose, stop ALFAXAN MULTIDOSE IDX administration and administer treatment as indicated by the patient’s clinical signs. Cardiovascular depression should be treated with plasma expanders, pressor agents, anti-arrhythmic agents or other techniques as appropriate for the treatments of the clinical signs.\nHuman safety: Not for human use. Keep out of the reach of children.\nALFAXAN MULTIDOSE IDX should be managed to prevent the risk of diversion, through such measures as restriction of access and the use of drug accountability procedures appropriate to the clinical setting. Exercise caution to avoid accidental self‑injection. Overdose is likely to cause cardiorespiratory depression (such as hypotension, bradycardia and\u002F or apnea). Remove the individual from the source of exposure and seek medical attention. Respiratory depression should be treated by artificial ventilation and oxygen. Avoid contact of this product with skin, eyes, and clothes. In case of contact, eyes and skin should be liberally flushed with water for 15 minutes. Consult a physician if irritation persists. In the case of accidental human ingestion, seek medical advice immediately and show the package insert or the label to the physician.\nThe Safety Data Sheet (SDS) contains more detailed occupational safety information. To report adverse reactions in users or to obtain a copy of the SDS for this product call 1-888-963-8471.\nNote to physician: This product contains an injectable anesthetic.",{"id":111,"kind":112,"statement":113,"species":10,"limitation":10,"source_label":50},20004,"adverse_reaction","Adverse Reactions in Cat Field Study\nAdverse Reaction\nNumber of Catsa = 207\nHypotension (≤90 mm Hg)\n92\nTachycardia (≥ 180 bpm)\n61\nApnea (≥ 30 seconds)\n32 (of 202)\nHypertension (> 165 mm Hg)\n23\nBradypnea (RR\u003C 10 breaths\u002Fmin)\n16\nApnea (≥ 60 seconds)\n12 (of 202)\nBradycardia (≤90 beats\u002Fmin)\n10\nHypothermia (\u003C97°F)\n10\nHypoxia (SpO2 \u003C85%)\n4\nEmesis\n1\nUnacceptable Anesthesia Quality\n1\naEach cat may have experienced more than one adverse reaction\nAdditional adverse reactions for cats included vocalization, paddling, and muscle tremors. One cat that experienced tachycardia and hypoxia during anesthesia was euthanized 3 days later due to carcinoma involving the liver, pancreas and common bile duct. The relationship of the original tachycardia during anesthesia and the carcinoma is unknown.\nAdverse Reactions in Dog Field Study\nAdverse Reaction\nNumber of Dogsa = 182\nBradypnea (RR\u003C 10 breaths\u002Fmin)\n89\nApnea (≥ 30 seconds)\n55 (of 137)\nHypertension (> 165 mm Hg)\n54\nTachycardia (≥ 180 bpm)\n49\nApnea (≥ 60 seconds)\n34 (of 137)\nHypotension (≤70 mm Hg)\n32\nHypothermia (\u003C97°F)\n28\nBradycardia (≤70 beats\u002Fmin)\n24\nHypoxia (SpO2 \u003C85%)\n4\nLack of Effectiveness\n3\nUnacceptable Anesthesia Quality\n1\nEmesis\n1\naEach dog may have experienced more than one adverse reaction\nAdditional adverse reactions for dogs included vocalization, paddling, and muscle tremors.\nTo report adverse reactions or to obtain a copy of the SDS for this product call 1-888-963-8471.\nFor additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or http:\u002F\u002Fwww.fda.gov\u002Freportanimalae.",{"id":115,"kind":112,"statement":116,"species":10,"limitation":10,"source_label":58},20005,"Specific adverse reactions described in the referenced literature are listed in the Dosage and Administration section of the product insert.\nTo report adverse reactions or to obtain a copy of the SDS for this product call 1‑844‑253‑2926. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1‑888‑FDA‑VETS or online at http:\u002F\u002Fwww.fda.gov\u002Freportanimalae.",{"id":118,"kind":112,"statement":119,"species":10,"limitation":10,"source_label":58},20006,"Specific adverse reactions described in the referenced literature are listed in the Dosage and Administration section of the product insert.",{"id":121,"kind":122,"statement":123,"species":10,"limitation":10,"source_label":50},20007,"mechanism_of_action","ALFAXAN MULTIDOSE is a reformulation of previously approved, single-use ALFAXAN (NADA 141-342) which contained no antimicrobial preservative. The bioequivalence of ALFAXAN (unpreserved) and ALFAXAN MULTIDOSE following administration of 5 mg\u002Fkg IV was demonstrated in a two sequence, two period crossover study in 24 cats (see EFFECTIVENESS). The bioequivalence of ALFAXAN (unpreserved) and ALFAXAN MULTIDOSE following administration of 3 mg\u002Fkg IV was demonstrated in a two sequence, two period crossover study in 24 dogs (see EFFECTIVENESS).",[125],{"id":126,"documentId":127,"slug":128,"name":129},997,"ywj0wus1xwn853kgwcaukbul","other-general-anesthetics","Other general anesthetics",[],[],[]]